Valeant stock surged as much as 6% Tuesday on the news. Take Dendreon, which makes cancer immunotherapy treatment Provenge, …
Valeant
Basically, if Valeant would have sold Dendreon in May of last year for the same $820 million ... I have no business relationship with any company whose stock is mentioned in this article.
Valeant
Selling the Dendreon business will help Valeant simplify and focus on ... Register now to create your own custom streaming stock watchlist. …
Valeant
Valeant had bought Dendreon two years ago for $400 million ...
asset sales
Merck is a Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks ... The other agreement will see Valeant selling off the outstanding equity interests in Dendreon Pharmaceuticals to the Sanpower …
Merck
The seemingly endless stream of bad news caused the stock to tumble more than 85% in 2016; however, management's news today could …
Valeant Pharmaceuticals
Dendreon (DNDN) stock opened slightly higher this morning, despite the fact that Dendreon earnings for Q3 rolled in even worse than expected. Product revenue for DNDN — which is to say revenue from its only …
Shares of the company have plunged more than 90 percent from the stock’s high of $257 in July 2015. The sale of Canada-based Valeant’s skincare …
Valeant stock
Investors in Dendreon Corp (NASD: DNDN) saw new options begin trading today, for the November 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DNDN options …